Overreliance of biotechs on large CDMOs could cause overruns of up to 40%, an industry expert has warned. 

Madhav Bhutada, Director of Shilpa Biologicals, urged biotechs to take a broader and earlier approach to CDMO selection as funding conditions improve across the sector.  

Bhutada said many emerging biopharma innovators – particularly those developing more complex modalities such as bispecific and trispecific antibodies – continue to rely heavily on a small number of well-known large CDMOs. These biotechs frequently underestimate the operational constraints of large-scale CDMOs, particularly around capacity allocation and managing changes outside agreed scope. 

Shilpa Biologicals estimates that overruns add 20–40% to budgets in some cases and materially delay entry into clinical trials. 

“Too often, a biotech operating on a tight budget assumes a perfect manufacturing scenario with no challenges,” Bhutada said. “This is where problems begin.” 

Early-stage planning around scope definition and out-of-scope work could be increasingly important, as unforeseen changes remain a common driver of both delay and budget pressure in biologics development programmes. 

While timelines at the largest CDMOs may, in ideal scenarios, be only around six months, in practice 12 months is often more realistic once issues arise.  

By contrast, smaller CDMOs will often complete comparable work in around six to nine months, typically at lower costs, as they are able to provide a dedicated team of scientists specifically focused on rapid troubleshooting. 

This shift towards more diversified CDMO strategies is also increasingly reflected across the wider industry, with CMC consultants and investors now placing greater emphasis on CDMO selection and network design during due diligence.  

“It is not only cost, but time lost, that is critical to long-term commercial viability,” Bhutada added.  

“So I predict you will see both VCs and consultants at BIO now factoring this into their decision-making triage on biotech investments.”